Healthcare [ 12/13 ] | Drug Manufacturers - Specialty & Generic [ 83/159 ]
NASDAQ | Common Stock
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 29, 24 | 0.89 Increased by +11.25% | 0.88 Increased by +1.14% |
| Nov 2, 23 | 0.72 Increased by +12.50% | 0.78 Decreased by -7.69% |
| Aug 2, 23 | 0.78 Increased by +52.94% | 0.76 Increased by +2.63% |
| May 3, 23 | 0.53 Decreased by -17.19% | 0.62 Decreased by -14.52% |
| Feb 28, 23 | 0.80 Decreased by -17.53% | 0.83 Decreased by -3.61% |
| Nov 3, 22 | 0.64 Decreased by -11.11% | 0.76 Decreased by -15.79% |
| Aug 3, 22 | 0.51 Decreased by -33.77% | 0.85 Decreased by -40.00% |
| May 4, 22 | 0.64 Increased by +20.75% | 0.83 Decreased by -22.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 181.24 M Increased by +5.40% | 24.87 M Increased by +346.19% | Increased by +13.72% Increased by +333.57% |
| Sep 30, 23 | 163.93 M Decreased by -2.11% | 10.86 M Increased by +1.67 K% | Increased by +6.62% Increased by +1.70 K% |
| Jun 30, 23 | 169.47 M Increased by +0.03% | 25.76 M Increased by +29.62% | Increased by +15.20% Increased by +29.58% |
| Mar 31, 23 | 160.34 M Increased by +1.49% | -19.54 M Decreased by -386.12% | Decreased by -12.18% Decreased by -381.92% |
| Dec 31, 22 | 171.96 M Increased by +8.02% | -10.10 M Decreased by -96.96% | Decreased by -5.87% Decreased by -82.34% |
| Sep 30, 22 | 167.47 M Increased by +31.12% | -693.00 K Decreased by -103.92% | Decreased by -0.41% Decreased by -102.99% |
| Jun 30, 22 | 169.41 M Increased by +24.94% | 19.88 M Increased by +4.17% | Increased by +11.73% Decreased by -16.63% |
| Mar 31, 22 | 157.99 M Increased by +32.74% | 6.83 M Decreased by -34.15% | Increased by +4.32% Decreased by -50.39% |